Nortriptyline

證據等級: L5

預測適應症: 2 個

Nortriptyline: From Unspecified Indication to Attention-Deficit/Hyperactivity Disorder (ADHD)

One-Sentence Summary

Nortriptyline is a tricyclic antidepressant (TCA); its original approved indication is not recorded in this evidence pack. The TxGNN model predicts it may be effective for Attention-Deficit/Hyperactivity Disorder (ADHD), with 0 registered clinical trials but 20 supporting publications (including 1 completed controlled trial), currently backing this direction.

Quick Overview

Item	Content
Original Indication	Not recorded in evidence pack (original_indications and original_moa both flagged as data gaps)
Predicted New Indication	Attention-Deficit/Hyperactivity Disorder (ADHD)
TxGNN Prediction Score	99.42%
Evidence Level	L2
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Formal DrugBank mechanism-of-action documentation is not available in this evidence pack (flagged as a High-severity data gap). However, the model-supplied mechanistic rationale indicates that nortriptyline is a tricyclic antidepressant (TCA) that primarily inhibits norepinephrine (NE) reuptake, with secondary inhibition of serotonin (5-HT) reuptake. This is consistent with literature context in the evidence pack — for example, a PET imaging study (PMID 24345533) confirms nortriptyline’s role as a NET-selective TCA in the treatment of depression, while noting NET’s relevance to both depression and ADHD.

ADHD pathophysiology is understood to involve prefrontal cortex norepinephrine/dopamine system hypofunction. Because nortriptyline’s NE reuptake inhibition mechanism parallels that of atomoxetine (an approved non-stimulant ADHD therapy), the pharmacological rationale for repurposing is plausible. Notably, several publications in this pack highlight nortriptyline’s specific advantage in ADHD patients with comorbid tic disorder or Tourette’s syndrome, since — unlike central stimulants — it does not appear to exacerbate tics (PMID 8428873, PMID 8444763).

This mechanism does carry a known limitation: TCAs have established cardiac conduction effects (QTc prolongation risk), which is a key consideration for pediatric use and is addressed further below.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
11052409	2000	RCT	J Child Adolesc Psychopharmacol	Controlled study of nortriptyline efficacy and tolerability in pediatric ADHD
22700161	2012	RCT	Pediatr Nephrol	Randomized double-blind controlled trial of nortriptyline for enuresis in children with ADHD
25238582	2014	Review (Cochrane)	Cochrane Database Syst Rev	Systematic review of tricyclic antidepressants for ADHD in children/adolescents
15064003	2004	Review	Psychiatr Clin North Am	Reviews nonstimulant ADHD treatments; notes nortriptyline among established noradrenergic TCA options, limited by narrow therapeutic index and cardiovascular toxicity
22303520	2012	Review	Ann Clin Psychiatry	CANMAT task force recommendations for managing mood disorders with comorbid adult ADHD
15794722	2005	Review	Expert Opin Drug Saf	Safety review of non-stimulant ADHD agents including TCAs
7807071	1995	Systematic Review	J Nerv Ment Dis	Systematic assessment of tricyclic antidepressants in adult ADHD
8444763	1993	Case series	J Am Acad Child Adolesc Psychiatry	Chart review of 58 ADHD cases treated with nortriptyline
8428873	1993	Cohort	J Am Acad Child Adolesc Psychiatry	Nortriptyline in children with ADHD and comorbid tic disorder/Tourette’s syndrome
4075308	1985	Cohort	Clin Neuropharmacol	Early report on nortriptyline in attention deficit disorder

US Market Information

No license records available (total_licenses: 0, market status: 未上市/Not Marketed).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One completed controlled trial (PMID 11052409) plus a Cochrane systematic review and consistent mechanistic/cohort evidence support ADHD as a biologically plausible repurposing direction for nortriptyline, particularly in patients with comorbid tic disorders — meeting the L2 evidence bar. However, a second predicted subtype indication, “ADHD, inattentive type,” has no supporting trials or literature (evidence level L5, decision stage S0) and should remain on Hold.

To proceed, the following is needed:

TFDA label warnings/contraindications (Blocking data gap — required before this candidate can enter S1 safety review)
Official DrugBank mechanism-of-action documentation (High priority — currently only model-inferred rationale is available)
Confirmation of Taiwan registration/licensing pathway, as nortriptyline currently holds no active license (0 NDAs, 未上市)
A cardiac safety monitoring plan (baseline and follow-up ECG) given the TCA class QTc-prolongation risk, especially for pediatric ADHD use
Additional controlled trial evidence in adult ADHD populations, as existing RCT evidence is limited to pediatric patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.